30
Participants
Start Date
July 15, 2023
Primary Completion Date
December 31, 2025
Study Completion Date
December 31, 2026
CD70-targeting CAR-T cells
"Dose escalation:~Dose1 (1×10\^6 cells/kg) ,Dose 2(3×10\^6 cells/kg) ,Dose 3 (1×10\^7 cells/kg)~Doseexpansion: RP2D~Drug: Fludarabine~Intravenous fludarabine 25-30 mg/m\^2/day on days 5, -4, and -3.~Drug: Cyclophosphamide~Intravenous cyclophosphamide 300-500 mg/m\^2/day on days -5, -4, and -3."
RECRUITING
China, Beijing
UTC Therapeutics Inc.
INDUSTRY
Chinese PLA General Hospital
OTHER